RBC Capital Reiterates Outperform on Oncolytics Biotech, Maintains C$6 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Douglas Miehm has reiterated an Outperform rating on Oncolytics Biotech (TSX:ONC) and maintained a price target of C$6.
August 05, 2024 | 3:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Oncolytics Biotech (TSX:ONC) and maintained a price target of C$6.
The reiteration of an Outperform rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100